|
Volumn 36, Issue 2 SUPPL., 2004, Pages S414-S419
|
Therapeutic monitoring of cyclosporine in kidney transplantation: The Halifax experience
|
Author keywords
[No Author keywords available]
|
Indexed keywords
AZATHIOPRINE;
BASILIXIMAB;
CYCLOSPORIN A;
INTERLEUKIN 2 RECEPTOR ANTIBODY;
LYMPHOCYTE ANTIBODY;
MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;
POLYCLONAL ANTIBODY;
PREDNISONE;
RAPAMYCIN;
TACROLIMUS;
THYMOCYTE ANTIBODY;
ACUTE GRAFT REJECTION;
AREA UNDER THE CURVE;
CLINICAL TRIAL;
DOSIMETRY;
DRUG ABSORPTION;
DRUG BIOAVAILABILITY;
DRUG BLOOD LEVEL;
DRUG EFFICACY;
DRUG EXPOSURE;
DRUG MEGADOSE;
DRUG MONITORING;
DRUG SAFETY;
DRUG TOLERABILITY;
GRAFT SURVIVAL;
HEART TRANSPLANTATION;
HUMAN;
HYPERLIPIDEMIA;
IMMUNOSUPPRESSIVE TREATMENT;
KIDNEY DISEASE;
KIDNEY GRAFT REJECTION;
KIDNEY TRANSPLANTATION;
LIVER TRANSPLANTATION;
LOW DRUG DOSE;
NEPHROTOXICITY;
PRIORITY JOURNAL;
REVIEW;
|
EID: 1642281137
PISSN: 00411345
EISSN: None
Source Type: Journal
DOI: 10.1016/j.transproceed.2004.01.055 Document Type: Article |
Times cited : (4)
|
References (39)
|